

Patient NAME : Mr Dummy - PL259A	Report STATUS : Final Report
DOB/Age/Gender : 25 Y/Male	Barcode NO : ZF558196
Patient ID / UHID : 10646175/OF10646175	Sample Type : Serum
Referred BY : Self	Report Date : Dec 03, 2024, 05:19 PM.
Sample Collected : Dec 03, 2024, 03:21 PM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Male Hormone Profile- Essential

TSH 3rd Generation

Thyroid Stimulating Hormone (Ultrasensitive) Chemiluminescence Immuno Assay (CLIA)	3.21	µIU/mL	0.4 - 4.2
---	------	--------	-----------

Interpretation:

Pregnancy	Reference ranges TSH
1 st Trimester	0.1 - 2.5
2 ed Trimester	0.2 - 3.0
3 rd Trimester	0.3 - 3.0

Note:

TSH levels are subject to circadian variation, reaching peak levels between 2-4 am. and at a minimum between 6-10 pm. The variation is of 50 %, hence time of the day has influence on the measured serum TSH concentrations.

Clinical Use:

- Diagnose Hypothyroidism and Hyperthyroidism
- Monitor T4 replacement or T4 suppressive therapy
- Qunatify TSH levels in the subnormal range

Increased Levels : Primary hypothyroidism, Subclinical hypothyroidis, TSH dependent Hyperthyroidism, Thyroid hormone resistance

Decreased Levels: Grace disease, Autonomous thyroid hormone secretion, TSH deficiency

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mr Dummy - PL259A	Report STATUS : Final Report
DOB/Age/Gender : 25 Y/Male	Barcode NO : ZF558196
Patient ID / UHID : 10646175/OF10646175	Sample Type : Serum
Referred BY : Self	Report Date : Dec 03, 2024, 05:19 PM.
Sample Collected : Dec 03, 2024, 03:21 PM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Prolactin (PRL)

Prolactin ECLIA	18.67	ng/mL	Men 4.04 - 15.2 Women(Not-pregnant)4.79 - 23.3
--------------------	-------	-------	---

Interpretation:

Note:

1. Since prolactin is secreted in a pulsatile manner and is also influenced by a variety of physiologic stimuli, it is recommended to test 3 specimens at 20-30 minute intervals after pooling.
2. Major circulating form of Prolactin is a nonglycosylated monomer, but several forms of Prolactin linked with immunoglobulin occur which can give falsely high Prolactin results.
3. Macroprolactin assay is recommended if prolactin levels are elevated, but signs and symptoms of hyperprolactinemia are absent or pituitary imaging studies are normal

Clinical Use

- Diagnosis & management of pituitary adenomas
- Differential diagnosis of male & female hypogonadism

Increased Levels

- **Physiologic:** Sleep, stress, postprandially, pain, coitus
- **Systemic disorders:** Chest wall or thoracic spinal cord lesions, Primary / Secondary hypothyroidism, Adrenal insufficiency, Chronic renal failure, Cirrhosis
- **Medications:** **Psychiatric medications** like Phenothiazine, Haloperidol, Risperidone, Domperidone, Fluoxetine, Amitriptylene, MAO inhibitors etc.,

Antihypertensives: Alphamethyldopa, Reserpine, Verapamil

Opiates: Heroin, Methadone, Morphine, Apomorphine

Cimetidine / Ranitidine

- Prolactin secreting pituitary tumors: Prolactinoma, Acromegaly
- Miscellaneous: Epileptic seizures, Ectopic secretion of prolactin by non-pituitary tumors, pressure / transection of pituitary stalk, macroprolactinemia
- Idiopathic

Decreased levels

- Pituitary deficiency: Pituitary necrosis / infarction
- Bromocriptine administration
- Pseudohypoparathyroidism

Testosterone Total

Testosterone Total CLIA	296.0	ng/dL	249 - 836
----------------------------	-------	-------	-----------

Interpretation:

Age in Years	Reference Ranges ng/dL
Males 20-49	249 - 836

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mr Dummy - PL259A

DOB/Age/Gender : 25 Y/Male

Patient ID / UHID : 10646175/OF10646175

Referred BY : Self

Sample Collected : Dec 03, 2024, 03:21 PM

Report STATUS : Final Report

Barcode NO : ZF558196

Sample Type : Serum

Report Date : Dec 03, 2024, 05:19 PM.

Test Description	Value(s)	Unit(s)	Reference Range
Males ≥ 50 years	193 - 740		
Females 20-49	8.4 - 48.1		
Females ≥ 50	2.9- 40.8		

Reference values for Males (7-18 years) characterized by Tanner Stage

Tanner Stage	5-95th percentiles (ng/dL)
1	2.31 - 30.28
2	3.75 - 282.06
3	8.65 - 681.78
4	17.88 - 785.6
5	13.27 - 906.15

Reference values for females (8-18 years) characterized by Tanner Stage

Tanner Stage	5-95th percentiles (ng/dL)
1	0.58 - 33.17
2	4.33 - 23.07
3	6.92 - 42.97
4	15.29 - 1.86
5	15.00 - 102.38

Note

- All applications that require measurement of very low level of testosterone (eg hypogonadal men, children, virilization or intersex disorders in women etc) recommended test is Testosterone total, Ultrasensitive
- LC-MS/MS is the gold standard for steroid hormone assays due to increased sensitivity & specificity as compared to immunoassays

Clinical Use

Assessment of testicular function in males

Increased levels

- Precocious puberty (Males)
- Androgen resistance
- Testotoxicosis
- Congenital Adrenal Hyperplasia

Decreased levels

- Delayed puberty (Males)
- Gonadotropin deficiency
- Testicular defects
- Systemic diseases

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mr Dummy - PL259A	Report STATUS : Final Report
DOB/Age/Gender : 25 Y/Male	Barcode NO : ZF558196
Patient ID / UHID : 10646175/OF10646175	Sample Type : Serum
Referred BY : Self	Report Date : Dec 03, 2024, 05:19 PM.
Sample Collected : Dec 03, 2024, 03:21 PM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

HOMA-IR.

GLUCOSE FASTING <i>Plasma, Hexokinase</i>	88.0	mg/dL	<100
Insulin (Fasting) <i>CMA</i>	8.9	μU/mL	<25.0
HOMA IR Index <i>Calculated</i>	1.9		<2.5

Interpretation:

1. The HOMA model is used to yield an estimate of insulin sensitivity and beta cell function from fasting plasma insulin and glucose concentrations.
2. Insulin resistance is a state in which normal concentrations of insulin produce a subnormal biologic response.
3. Levels of Insulin are increased in insulinomas, factitious hypoglycemia, insulin autoimmune syndrome, acromegaly (after ingestion of glucose), Cushings syndrome, corticosteroid administration and levodopa usage.
4. Levels of Insulin are depressed to absent in diabetes mellitus, pituitary tumors and chronic pancreatic diseases i.e. cystic fibrosis.
5. Insulin/ C-peptide ratio is used for differentiating between factitious hypoglycemia and insulinomas where a ratio < 1.0 indicates insulinoma; but results may vary in renal failure.
6. Antibodies to insulin form in longstanding diabetes mellitus treated with insulin hence in these patients monitoring insulin levels gives better prognosis.

Uses of HOMA Values:

1. To assess the risk of development of diabetes. It allows assessment of inherent beta cell function and insulin sensitivity and characterizes the pathophysiology in those with abnormal glucose tolerance.
2. It can be used to assess response to diet or oral drug therapy.

Remarks:

1. Insulin glucose HOMA model cannot be used in those taking exogenous insulin. Under such circumstances, the C peptide HOMA model which uses C peptide to reflect endogenous insulin secretions could be used.

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Patient NAME : Mr Dummy - PL259A	Report STATUS : Final Report
DOB/Age/Gender : 25 Y/Male	Barcode NO : ZF558196
Patient ID / UHID : 10646175/OF10646175	Sample Type : Serum
Referred BY : Self	Report Date : Dec 03, 2024, 05:19 PM.
Sample Collected : Dec 03, 2024, 03:21 PM	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

LH / FSH Ratio

Luteinising Hormone-LH <i>CMIA</i>	2.37	mIU/mL	Normal Males - 0.57 - 12.07
Follicle Stimulating Hormone-FSH <i>CMIA</i>	1.21	mIU/mL	Males 0.95 - 11.95
LH / FSH Ratio	1.96		

Interpretation:

- Ratio of LH to FSH > 2.50 indicates the presence of PCOS.
- Polycystic Ovary Syndrome (PCOS) is a complex syndrome and each of the clinical phenotype is associated with different patterns of steroid hormones. It is likely that simultaneous measurement of multiple androgens (steroid/androgen profiling with highly specific and sensitive method LC-MS/MS) be more sensitive for detecting PCOS-related androgen excess and for predicting metabolic risk.
- Women with Non-classical Congenital Adrenal Hyperplasia (NC-CAH) due to 21-hydroxylase deficiency and women with PCOS have similar clinical presentation, with hyperandrogenism, oligomenorrhea, and polycystic ovaries. The screening tool to distinguish NC-CAH from PCOS is the basal 17-OHP levels and the ACTH stimulation test.

Comments:

Polycystic Ovarian Syndrome (PCOS) affects 5-10% of women of reproductive age, making it the most common endocrine disorder of women in this age group. It is characterized by amenorrhea, hirsutism and infertility. It is caused by a complex interaction of abnormalities in gonadotropins, androgens & estrogens. Insulin resistance and hyperinsulinemia contribute significantly to its pathophysiology. Although PCOS is associated with hyperandrogenism & infertility early in life, it is a harbinger of a lifelong condition that can lead to serious sequelae such as Endometrial or Ovarian cancer, Diabetes mellitus & Coronary artery disease. Thus, it is crucial to diagnose PCOS early in its course not only to recognize but also to delay or arrest its metabolic sequelae

Clinical use :

- In Diagnosis of gonadal dysfunction and management of infertility

Increased level : Primary hypogonadism

Decreased level :

- Hypothalamic GnRH deficiency
- Hypopituitarism

*** End Of Report ***

Booking Centre :- REDCLIFFE - ILC NOIDA

Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301



Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.